Table of Contents
As thousands of biopharma leaders gather in Boston next week for BPI East, I believe we’re approaching a significant inflection point for our industry.
For years, the conversation centered on scientific innovation. Today, the challenge is no longer whether we can develop breakthrough therapies. It’s whether we can develop and manufacture them fast enough.
The FDA has made its intentions abundantly clear through Operation TrialBlazer and, most recently, the launch of the new Expedited IND Pilot Program. The agency is actively exploring ways to accelerate the path from drug discovery to first-in-human studies by enabling rolling reviews, earlier regulatory engagement, and stronger collaboration between sponsors and experts. The goal is straightforward: reduce development timelines while maintaining scientific rigor and patient safety.
As BPI East begins, here are my three predictions for the conversations that will dominate the conference.
Prediction #1: Speed to Clinic Will Become the Industry’s Most Important KPI
Historically, companies optimized around technical milestones such as cell line development, process validation, IND submission, or GMP manufacturing readiness. Increasingly, however, investors, regulators, and sponsors are focusing on a different metric:
How quickly can a therapy reach first-in-human studies?
The FDA’s Expedited IND Pilot reflects a growing recognition that development timelines matter. The agency has openly acknowledged that first-in-human trials often start significantly faster in other global markets and is taking steps to help U.S. innovators accelerate development.
This shift means that development speed is no longer simply an operational objective.
It is a competitive advantage.
Organizations that can compress development, manufacturing, and regulatory readiness into an integrated pathway will create value faster, generate clinical data sooner, and make better portfolio decisions earlier.
At BPI East, expect discussions to move beyond scientific feasibility and toward execution efficiency.
Prediction #2: Manufacturing Will Become the Rate-Limiting Step in Accelerated Development
Regulatory acceleration without manufacturing acceleration creates a bottleneck.
The industry has spent years improving discovery platforms, AI-enabled design, analytics, and regulatory pathways. Yet many manufacturing models still rely on lengthy handoffs between multiple vendors, traditional development sequences, and infrastructure originally designed for commercial-scale products rather than early clinical programs.
As regulators continue introducing initiatives such as Operation TrialBlazer and the CMC Development and Readiness Pilot (CDRP), the spotlight will increasingly turn toward manufacturing readiness.
The question will become:
Can manufacturing keep pace with the FDA’s vision?
Many emerging biotechs still face timelines that exceed a year before GMP material is available for clinical studies, often requiring investments exceeding $5 million before meaningful human data is generated.
The industry needs a new manufacturing model built specifically for accelerated development, not simply faster versions of legacy approaches.
Prediction #3: Right-Sized Manufacturing Will Create an Entirely
New Category of Capacity
For decades, biologics manufacturing has been built around the assumption that bigger is better.
That model made sense when the industry focused primarily on blockbuster products and large commercial demand.
Today’s reality looks very different.
Precision medicines, orphan indications, novel biologics, and accelerated clinical programs require agility, flexibility, and capital efficiency.
I believe BPI East will showcase the emergence of a new manufacturing category:
Right-sized GMP manufacturing designed specifically for first-in-human development.
This is precisely why GBI developed SmartScale™ GMP Solutions.
Built in collaboration with ATUM and Thomson Instrument Company, SmartScale™ combines advanced cell line technology, stable pool manufacturing strategies, streamlined scale-up platforms, integrated analytical services, quality systems, and GMP manufacturing under one roof.
The result is a purpose-built development-to-clinic ecosystem capable of delivering GMP material for first-in-human studies in as little as eight months while significantly reducing cost and complexity.
Rather than forcing innovators into oversized infrastructures, SmartScale™ was designed to align with the future of drug development: faster decisions, earlier clinical data, lower capital requirements, and greater flexibility.
Final Thought
The FDA’s latest Expedited IND Pilot announcement sends a powerful signal to the industry:
The future belongs to organizations that can move faster without
compromising quality.
Scientific innovation is accelerating.
Regulatory innovation is accelerating.
Now manufacturing must accelerate too.
My prediction is that BPI East 2026 will mark the moment our industry collectively recognizes that manufacturing capacity is no longer just infrastructure.
It is strategy.
It is a competitive advantage.
And it may ultimately determine which therapies reach patients first.
I’m looking forward to discussing these trends with industry leaders this week in Boston. If you’re attending BPI East, let’s connect and talk about how the industry can build the manufacturing capacity needed for the next generation of accelerated drug development.
Attending BPI East 2026?
Click here or visit GBI Biomanufacturing at Booth #1627 to meet our team and discuss emerging industry trends, SmartScale™ GMP Solutions, rapid small-scale production platforms, and how we can help accelerate your path from development to IND and beyond!
Chandra Kelley brings more than 25 years of experience in the biotechnology and biopharmaceutical industry, where she has built a reputation as a strategic, relationship‑driven leader who consistently accelerates organizational growth. She leads GBI’s commercial strategy, business development organization, client engagement initiatives, and long‑term growth planning as the company continues to expand its capabilities and market presence. With a career spanning business development, strategic partnerships, and team leadership, Chandra brings a rare blend of commercial acumen, scientific literacy, and people‑centered leadership to high‑growth organizations. She is driven by an unwavering dedication to delivering unparalleled service to clients and patients, reflected in her success building strategic partnerships, leading global marketing and commercial development initiatives, and strengthening market positioning for companies navigating pivotal expansion. Prior to joining GBI Bio, Chandra held senior commercial development roles at KBI Biopharma, Pfanstiehl, and SAFC, where she led global growth strategies and expanded key client relationships across the biopharmaceutical sector. She also serves as an Advisory STEM Board Member at Point Loma Nazarene University (PLNU), where she earned her BS in Biology, demonstrating her commitment to advancing STEM education and developing future scientific leaders.
